A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
← catalyst calendarNCT06607185 · readout ≤ 1,261 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
750estimated
Sites
45
Countries
Belgium, France, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-21 | actual | When the study began enrolling |
| Primary completion | Jan 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pancreatic Ductal Adenocarcinoma
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
- Drug: LY4066434.
- Drug: Cetuximab
- Drug: Nab paclitaxel
- Drug: Gemcitabine
- Drug: Oxaliplatin
- Drug: Leucovorin — also filed as Folinic Acid
- Drug: Irinotecan
- Drug: 5Fluorouracil
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Pemetrexed
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Dose-limiting Toxicities (DLTs)
measured During the first cycle of LY4066434 treatment (up to 28 days)
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
measured Up to approximately 5 years
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed